Enzyme/Prodrug Systems for Cancer Gene Therapy.
Ontology highlight
ABSTRACT: The use of enzyme/prodrug system has gained attention because it could help improve the efficacy and safety of conventional cancer chemotherapies. In this approach, cancer cells are first transfected with a gene that can express an enzyme with ability to convert a non-toxic prodrug into its active cytotoxic form. As a result, the activated prodrug could kill the transfected cancer cells. Despite the significant progress of different suicide gene therapy protocols in preclinical studies and early clinical trials, none has reached the clinic due to several shortcomings. These include slow prodrug-drug conversion rate, low transfection/transduction efficiency of the vectors and nonspecific toxicity/immunogenicity related to the delivery systems, plasmid DNA, enzymes and/or prodrugs. This mini
SUBMITTER: Malekshah OM
PROVIDER: S-EPMC5193473 | biostudies-literature | 2016 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA